Klonoff DC, Parkes JL, Kovatchev BP et al (2018) Investigation of the accuracy of 18 marketed blood glucose monitors. Diabetes Care 41: 1681–8
- This study was an independent assessment of the accuracy of marketed fingerstick blood glucose monitors. The 18 best-selling meters in the US, comprising approximately 90% of the market, were each in three separate studies in a round-robin.
- The devices were tested on a total of 1032 subjects. Recruitment was designed to obtain a wide range of glucose readings; therefore, participants included people with type 1 and type 2 diabetes, non-diabetic hyperglycaemia and no diabetes, and some were asked to come to the clinic fasting or 1–2 ours after a meal.
- In each study, glucose meter readings were compared with reference laboratory values. To pass the test, meters had to have ≥91% of readings within 15% of the reference value (or within 15 mg/dL [0.83 mmol/L] for values under 5.55 mmol/L), a standard similar to, but slightly more lenient than, current international and US standards.
- Only six of the 18 glucose meters met the accuracy standard in all three studies; five failed in one study, three failed in two studies and four failed in every study.
– The six most accurate meters, ranked by the proportion of data points that were within the protocol limits, were the Contour Next (Bayer), Accu-Chek Aviva Plus (Roche), Walmart ReliOn Confirm Micro (ARKRAY), CVS Advanced (AgaMatrix), Freestyle Lite (Abbott) and Accu-Chek SmartView (Roche). - The six top-performing meters also performed the best according to four other accuracy metrics.
- The authors conclude that a large number of blood glucose monitors that have previously received marketing authorisation are now insufficiently accurate to meet regulatory standards. Whether this is due to performance deterioration due to scaled-up production or other unknown issues, healthcare professionals should exercise caution when recommending meters for self-monitoring of blood glucose.
Attempts to achieve remission, or at least a substantial improvement in glycaemic control, should be the initial focus at type 2 diabetes diagnosis.
9 May 2024